Search

Displaying results 5921 - 5930 of 10000 in total
  1. Drug

    Bamlanivimab

    go.drugbank.com/drugs/DB15718
    ApprovedInvestigational

    [L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020. … [A224044, L20974] It is set to enter phase 3 clinical trials.

  2. Drug

    Xylitol

    go.drugbank.com/drugs/DB11195
    ApprovedInvestigational

    Xylitol is a non-fermentable sugar alcohol by most plaque bacteria, indicating that it cannot be fermented into cariogenic acid end-products [A32423]. … The recommended dose of xylitol for dental caries prevention is 6–10 g/day, and most adults can tolerate 40 g/day without adverse events [A22081].

    Mixtures: Fluor-a-day, Fluor-a-dayCategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis. … [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116]

    Synonyms: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s
  4. Drug

    Chymopapain

    go.drugbank.com/drugs/DB06752
    ApprovedWithdrawn

    [L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.

    Products: Chymodiactin Injection - 4 Nkat Units/2ml
  5. Drug

    Pergolide

    go.drugbank.com/drugs/DB01186
    ApprovedVet approvedWithdrawn

    It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. … The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor AgonistsProducts: PERGOLID-NEURAX 1 MG
  6. Drug

    Entacapone

    go.drugbank.com/drugs/DB00494
    ApprovedInvestigational

    Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. … When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration

    Mixtures: LEVODO CA E P100/25/200, LEVODO CA E P100/25/200Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  7. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    ApprovedInvestigational

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed

    Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal AntibodySynonyms: Immunoglobulin g1 (262-tyrosine,264-threonine,266-glutamic acid), anti-(human respiratory syncytial virus f protein) (human monoclonal rb1 .gamma.1-chain), disulfide with human monoclonal rb1 .kappa.
  8. Drug

    Technetium Tc-99m oxidronate

    go.drugbank.com/drugs/DB09139
    ApprovedWithdrawn

    [L1138] These complexes are formed by the binding of 99mTc to metal atoms of an organic molecule. … [L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981.

  9. Target

    Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1

    go.drugbank.com/bio_entities/BE0008997
    TargetHumans

    S-adenosyl-L-methionine-dependent methyltransferase that mediates mRNA cap1 2'-O-ribose methylation to the 5'-cap structure of mRNAs.

    Polypeptides: Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1Synonyms: Cap methyltransferase 1
  10. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high